2D 3D
	ID	DDInter2046
	Drug Type	small molecule
	Molecular Formula	C26H31Cl2N7O3
	Molecular Weight	560.475
	CAS Number	872511-34-7
	Description	Infigratinib is a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor. By inhibiting the FGFR pathway, which is often aberrated in cancers such as cholangiocarcinoma, infigratinib suppresses tumour growth.[A235174] Cholangiocarcinoma is the most common primary malignancy affecting the biliary tract and the second most common primary hepatic malignancy.[A198963] Infitratinib is a pan-FGFR inhibitor, as it is an ATP-competitive inhibitor of all four FGFR receptor subtypes.[A235174] On May 28, 2021, the FDA granted accelerated approval to infigratinib - under the market name Truseltiq - for the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved test.[L34304] This approval follows [pemigatinib], another FGFR inhibitor approved by the FDA for the same therapeutic indication.
	ATC Classification	L01EN03
IUPAC Name	3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)-1-methylurea
InChI	QADPYRIHXKWUSV-UHFFFAOYSA-N
Canonical SMILES	CCN1CCN(CC1)C1=CC=C(NC2=CC(=NC=N2)N(C)C(=O)NC2=C(Cl)C(OC)=CC(OC)=C2Cl)C=C1
Useful Links	DrugBank ChEBI PubChem Substance ChemSpider BindingDB Wikipedia ChEMBL ZINC